Status:
COMPLETED
Effect of Vitamin D Supplement on Disease Activity in SLE
Lead Sponsor:
Department of Medical Services Ministry of Public Health of Thailand
Conditions:
Vitamin D Deficiency
Hypocalcemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To study the effect of vitamin D supplementation on disease activity of SLE ( SLEDAI-2K ) and IL-6 level
Eligibility Criteria
Inclusion
- Age \> 18 year-old
- SLE classified by revised ACR criteria, SLICC 2012 criteria
- SLE patients who have mild to moderate disease activity ( clinical SLEDAI-2K 3-10 ) and has vitamin D level \< 40 ng/ml
- currently treated with stable dose of 1 or more of the following background medication : NSAIDs, anti-malarial, MMF, Azathioprine, methotrexate, cyclosporin for at least 1 month, corticosteroid \</= 20 mg/d of prednisolone or equivalent dose for at least 2 weeks
- received calciferol 20,000 IU/wk (1 cap) at least 12 weeks
Exclusion
- patients with chronic liver disease, CKD stage 3, bed ridden, malignancy
- patients who received drug that interfere with vitamin D metabolism
- poor drug compliance
- overlap with other connective tissue disease or a diagnosis of MCTD
- hx of vitamin D allergy
- hx on MTV or other supplementation
Key Trial Info
Start Date :
June 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05260255
Start Date
June 15 2021
End Date
December 1 2022
Last Update
January 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rajavithi Hospital
Bangkok, Bangkok, Thailand, 10400